Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Pancreas|August 4, 2021
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal AdenocarcinomaMargaret Kelsey Baron, Xuechen Wang, Christopher Nevala-Plagemann, et al.Redox Biology|January 8, 2014
Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancerJustin C Moser, Malvika Rawal, Brett A Wagner, et al.Melanoma Research|November 15, 2014
The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanomaJustin C Moser, Jose S Pulido, Roxana S Dronca, et al.Cancer Medicine|November 3, 2019
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumabJustin C Moser, Danli Chen, Siwen Hu-Lieskovan, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 15, 2025
Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint InhibitorsYusra F Shao, Yasmine Baca, Andrew Hinton, et al.Cancer Research|July 15, 2022
The Mechanisms of Action of Tumor Treating FieldsJustin C Moser, Ellaine Salvador, Karina Deniz, et al.Annals of Diagnostic Pathology|July 13, 2016
c-Met expression and MET amplification in malignant pleural mesotheliomaMelanie C Bois, Aaron S Mansfield, William R Sukov, et al.Plos One|March 18, 2015
Development and external validation of a prognostic nomogram for metastatic uveal melanomaSara Valpione, Justin C Moser, Raffaele Parrozzani, et al.Histopathology|June 22, 2020
Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanomaKabeer K Shah, Jadee L Neff, Lori A Erickson, et al.Cancer Medicine|September 8, 2017
Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011Elizabeth Ann L Enninga, Justin C Moser, Amy L Weaver, et al.Pageof 3